Blood Glucose Testing Market by Product Type (Blood Glucose Meters, Control Solutions, Lancets), Technology (Electrochemical Sensors, Optical Techniques, Thermal Techniques), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Blood Glucose Testing Market was valued at USD 21.21 billion in 2024 and is projected to grow to USD 23.40 billion in 2025, with a CAGR of 10.67%, reaching USD 47.76 billion by 2032.
An authoritative overview explaining how recent clinical, technological, and care-delivery shifts are redefining standard practice and procurement priorities for blood glucose testing
Blood glucose testing remains a foundational component of diabetes care and metabolic monitoring, underpinning clinical decision-making across acute and chronic care settings. Advances in sensing technology, coupled with evolving care models that shift monitoring into home and community environments, have changed how clinicians, patients, and payers approach glycemic control. In practice, these changes are manifest in a broader array of device forms, enhanced connectivity features, and expanded support services that together aim to increase adherence and improve clinical outcomes.
As health systems emphasize value-based care and remote monitoring, stakeholders face new imperatives to integrate device data with electronic health records and care pathways. Consequently, procurement teams and clinical leaders must balance device performance, usability, and interoperability against operational considerations such as supply continuity and regulatory compliance. This introduction frames the subsequent analysis by highlighting the interplay between technological progress, care delivery reform, and the practical constraints that shape adoption trajectories across settings.
How sensor evolution, digital health integration, and shifting reimbursement dynamics are collectively transforming clinical workflows and commercialization strategies within glucose monitoring
The landscape of blood glucose testing is undergoing transformative shifts driven by sensor innovation, software-enabled care, and consumer expectations for seamless experiences. Continuous sensing platforms have moved from niche use cases to mainstream consideration, elevating the role of real-time data streams in therapy optimization. Concurrently, improved sensor chemistry and signal processing algorithms have narrowed gaps in accuracy and calibration burden, enabling more consistent use across diverse patient populations. These advances, in turn, create new opportunities for integrated care pathways where clinicians can intervene earlier based on trend analysis rather than intermittent readings.
Moreover, digital health ecosystems are maturing, with device manufacturers increasingly partnering with software providers and payers to create value-based propositions. Interoperability standards and data governance considerations have become central to procurement discussions, as stakeholders seek both clinical utility and compliance with privacy frameworks. At the same time, shifting reimbursement policies and clinician training requirements influence adoption speed across care settings. Taken together, these dynamics constitute a structural shift from isolated device purchases toward platform-based investments that emphasize longitudinal data, care coordination, and measurable outcomes.
Detailed analysis of how 2025 tariff changes have reshaped supply chain strategies, procurement practices, and operational resilience measures across the glucose testing ecosystem
The imposition of new tariff measures in 2025 introduced an additional layer of complexity for manufacturers, distributors, and healthcare providers, reshaping supply chain considerations and commercial strategies. Tariff-driven cost pressures prompted many stakeholders to reassess sourcing strategies, with some prioritizing regional suppliers to mitigate exposure to cross-border levies. In parallel, manufacturers accelerated efforts to localize production capacity and to optimize component sourcing to preserve margins while maintaining quality standards.
Consequently, procurement teams confronted tighter negotiation windows and revisited contractual arrangements to incorporate tariff pass-through scenarios and inventory buffer planning. For clinical operations, the immediate effect was an increased emphasis on supplier diversification and contingency planning to ensure uninterrupted access to critical testing consumables and devices. Over the medium term, regulatory compliance and customs classification accuracy emerged as operational priorities, as misclassification can amplify cost impacts. In this environment, transparency across the supply chain, proactive engagement with customs authorities, and scenario-based financial modeling have become indispensable tools for stakeholders seeking stability amid tariff-driven uncertainty.
Comprehensive segmentation insights linking product categories, sensing technologies, end-user requirements, and distribution pathways to real-world adoption dynamics
Deconstructing the market by product type highlights distinct value propositions and adoption drivers across device classes. Blood glucose meters continue to serve as accessible point-testing tools for many patients, while control solutions and lancets play complementary roles in ensuring measurement reliability and user comfort. Test strips remain a primary consumable cost driver, and their availability and pricing dynamics affect daily adherence. Within sensors, the split between continuous glucose monitoring sensors and flash glucose monitoring sensors delineates different clinical use patterns: one emphasizes real-time alerts and trend analysis, while the other prioritizes on-demand scanning and simplified sensor lifecycles.
Assessing technology modalities reveals that electrochemical sensors dominate due to their maturity and cost-effectiveness, optical techniques are gaining traction where non-invasive approaches are prioritized, and thermal techniques are explored in niche applications for enhanced signal differentiation. When viewed through the end-user lens, diagnostic laboratories demand high-throughput, standardized processes and robust quality controls, home care prioritizes ease of use, affordability, and remote connectivity, and hospitals and clinics require devices that integrate with point-of-care workflows and electronic medical records. Distribution channels also shape access and patient experience; hospital pharmacies manage inpatient and integrated outpatient prescriptions, online pharmacies enable direct-to-consumer convenience and subscription models, and retail pharmacies support immediate access and point-of-purchase counseling. Together, these segments form a multi-dimensional picture in which product design, technology selection, user needs, and distribution logistics intersect to determine a device or solution’s real-world suitability and adoption potential.
Regionally tailored strategic implications highlighting how differing regulatory landscapes, payer models, and care delivery realities influence adoption across the Americas, Europe Middle East and Africa, and Asia Pacific
Regional performance and strategic priorities vary considerably, driven by healthcare system structure, regulatory regimes, and demographic trends. In the Americas, a large and diverse payer landscape places a premium on real-world evidence and reimbursement clarity, with clinical integration and patient support programs driving competitive differentiation. Across Europe, the Middle East & Africa, regulatory harmonization efforts coexist with varied market maturity, necessitating tailored entry strategies that account for local approval timelines, procurement practices, and clinician education needs. Vendors operating in this region often balance centralized product strategies with decentralized commercialization tactics to accommodate heterogeneous regulatory and reimbursement environments.
Asia-Pacific presents a mosaic of opportunities characterized by rapid technology adoption in some markets and constrained access in others, where affordability and distribution reach are primary concerns. Supply chain optimization and local partnerships are frequent strategic levers in the region, enabling faster scale-up while meeting diverse regulatory expectations. Across all regions, cross-border data governance, device interoperability, and local clinical guidelines influence how devices are deployed and supported. Thus, successful regional strategies blend global product standards with locally informed commercialization, regulatory, and patient engagement plans that respond to unique healthcare delivery realities.
Key competitive dynamics and corporate strategies that reveal how product innovation, strategic partnerships, and service ecosystems are reshaping vendor differentiation
Competitive dynamics in the sector are driven by a combination of product innovation, strategic partnerships, and service-oriented differentiation. Established device manufacturers continue to invest in incremental improvements in accuracy, sensor durability, and connectivity while forging alliances with digital health vendors to extend platform value. Concurrently, emerging technology firms are pushing the envelope on non-invasive sensing and advanced signal processing, compelling incumbents to accelerate research and development cycles.
Corporate strategies vary by firm but commonly emphasize regulatory approvals, payer engagement, and channel expansion. Strategic collaborations with healthcare systems and technology partners are increasingly common as companies seek integrated value propositions that include analytics, patient engagement, and adherence support. Additionally, supply chain resilience, quality certifications, and clinical evidence portfolios are critical competitive assets that influence procurement decisions. For buyers, differentiating between vendors increasingly depends on assessing their capability to deliver not just a device but an ecosystem that supports clinical workflows, data interoperability, and measurable outcomes over time.
Actionable strategic priorities that industry leaders should implement immediately to strengthen resilience, accelerate clinical adoption, and enhance long-term competitive positioning
Industry leaders can act on several priority areas to secure competitive advantage and improve patient outcomes. First, investing in interoperable data architectures and standardized APIs will ease integration with electronic health records and third-party analytics, enabling richer clinical insights and smoother workflows. Second, diversifying manufacturing and logistics footprints reduces exposure to tariff and supplier disruptions while improving responsiveness to regional demand shifts. Third, developing comprehensive reimbursement strategies that couple clinical evidence generation with payer engagement will accelerate adoption in value-conscious settings.
In parallel, companies should enhance user-centered design to increase adherence across home and clinic settings, pairing device improvements with education and engagement programs that support behavior change. Strategic partnerships-ranging from software integrators to local distribution partners-can expand reach and reduce time-to-market. Finally, embedding post-market surveillance and real-world evidence collection into product lifecycles will support continuous improvement, regulatory compliance, and stronger payer conversations. By aligning these actions with clear metrics and cross-functional governance, leaders can translate strategic intent into measurable operational advances.
A rigorous mixed-methods research approach detailing primary interviews, device and regulatory reviews, and triangulation processes that underpin the report’s findings
The research underpinning this executive summary combines qualitative and quantitative approaches designed to ensure robustness and triangulation. Primary research included structured interviews with clinical leaders, procurement specialists, and supply chain managers to capture firsthand insights into adoption drivers and operational constraints. These perspectives were complemented by device-level technical reviews and regulatory documentation analysis to assess compliance trajectories and product differentiation. Secondary research drew on publicly available regulatory filings, clinical guidelines, and device registries to validate themes and identify longitudinal trends.
Data integrity was maintained through cross-validation across sources and transparent documentation of assumptions and inclusion criteria. Geographic and segment sampling ensured that findings reflect a diversity of care settings and distribution models. Limitations include variable public disclosure practices across jurisdictions and evolving regulatory interpretations that may affect near-term milestones; consequently, readers are encouraged to consider the findings as a structured synthesis of current evidence rather than definitive predictions. Where possible, references to primary interview insights are anonymized to preserve confidentiality while retaining practical applicability for decision-makers.
Concise synthesis of how technological convergence and reimbursement realities are driving stakeholders to prioritize interoperability, evidence, and resilient commercialization approaches
The convergence of sensing advances, digital integration, and evolving care models positions blood glucose testing at an inflection point where devices are becoming components of broader clinical ecosystems rather than standalone products. This shift has operational implications across procurement, clinical workflows, and supply chain management, particularly as stakeholders navigate tariff-related uncertainties and region-specific regulatory landscapes. The cumulative effect is a market environment that rewards adaptability: manufacturers and providers that can combine technical excellence with interoperability, resilient logistics, and evidence-based reimbursement strategies are best placed to succeed.
Looking ahead, the emphasis on longitudinal data, patient-centric design, and value-based outcomes will continue to shape both commercial strategies and clinical adoption. Organizations that prioritize cross-functional collaboration, invest in real-world evidence generation, and pursue pragmatic partnerships will be better equipped to respond to regulatory changes and payer expectations. Ultimately, effective execution will require aligning product development, commercialization, and post-market support to deliver measurable improvements in care delivery and patient experience.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative overview explaining how recent clinical, technological, and care-delivery shifts are redefining standard practice and procurement priorities for blood glucose testing
Blood glucose testing remains a foundational component of diabetes care and metabolic monitoring, underpinning clinical decision-making across acute and chronic care settings. Advances in sensing technology, coupled with evolving care models that shift monitoring into home and community environments, have changed how clinicians, patients, and payers approach glycemic control. In practice, these changes are manifest in a broader array of device forms, enhanced connectivity features, and expanded support services that together aim to increase adherence and improve clinical outcomes.
As health systems emphasize value-based care and remote monitoring, stakeholders face new imperatives to integrate device data with electronic health records and care pathways. Consequently, procurement teams and clinical leaders must balance device performance, usability, and interoperability against operational considerations such as supply continuity and regulatory compliance. This introduction frames the subsequent analysis by highlighting the interplay between technological progress, care delivery reform, and the practical constraints that shape adoption trajectories across settings.
How sensor evolution, digital health integration, and shifting reimbursement dynamics are collectively transforming clinical workflows and commercialization strategies within glucose monitoring
The landscape of blood glucose testing is undergoing transformative shifts driven by sensor innovation, software-enabled care, and consumer expectations for seamless experiences. Continuous sensing platforms have moved from niche use cases to mainstream consideration, elevating the role of real-time data streams in therapy optimization. Concurrently, improved sensor chemistry and signal processing algorithms have narrowed gaps in accuracy and calibration burden, enabling more consistent use across diverse patient populations. These advances, in turn, create new opportunities for integrated care pathways where clinicians can intervene earlier based on trend analysis rather than intermittent readings.
Moreover, digital health ecosystems are maturing, with device manufacturers increasingly partnering with software providers and payers to create value-based propositions. Interoperability standards and data governance considerations have become central to procurement discussions, as stakeholders seek both clinical utility and compliance with privacy frameworks. At the same time, shifting reimbursement policies and clinician training requirements influence adoption speed across care settings. Taken together, these dynamics constitute a structural shift from isolated device purchases toward platform-based investments that emphasize longitudinal data, care coordination, and measurable outcomes.
Detailed analysis of how 2025 tariff changes have reshaped supply chain strategies, procurement practices, and operational resilience measures across the glucose testing ecosystem
The imposition of new tariff measures in 2025 introduced an additional layer of complexity for manufacturers, distributors, and healthcare providers, reshaping supply chain considerations and commercial strategies. Tariff-driven cost pressures prompted many stakeholders to reassess sourcing strategies, with some prioritizing regional suppliers to mitigate exposure to cross-border levies. In parallel, manufacturers accelerated efforts to localize production capacity and to optimize component sourcing to preserve margins while maintaining quality standards.
Consequently, procurement teams confronted tighter negotiation windows and revisited contractual arrangements to incorporate tariff pass-through scenarios and inventory buffer planning. For clinical operations, the immediate effect was an increased emphasis on supplier diversification and contingency planning to ensure uninterrupted access to critical testing consumables and devices. Over the medium term, regulatory compliance and customs classification accuracy emerged as operational priorities, as misclassification can amplify cost impacts. In this environment, transparency across the supply chain, proactive engagement with customs authorities, and scenario-based financial modeling have become indispensable tools for stakeholders seeking stability amid tariff-driven uncertainty.
Comprehensive segmentation insights linking product categories, sensing technologies, end-user requirements, and distribution pathways to real-world adoption dynamics
Deconstructing the market by product type highlights distinct value propositions and adoption drivers across device classes. Blood glucose meters continue to serve as accessible point-testing tools for many patients, while control solutions and lancets play complementary roles in ensuring measurement reliability and user comfort. Test strips remain a primary consumable cost driver, and their availability and pricing dynamics affect daily adherence. Within sensors, the split between continuous glucose monitoring sensors and flash glucose monitoring sensors delineates different clinical use patterns: one emphasizes real-time alerts and trend analysis, while the other prioritizes on-demand scanning and simplified sensor lifecycles.
Assessing technology modalities reveals that electrochemical sensors dominate due to their maturity and cost-effectiveness, optical techniques are gaining traction where non-invasive approaches are prioritized, and thermal techniques are explored in niche applications for enhanced signal differentiation. When viewed through the end-user lens, diagnostic laboratories demand high-throughput, standardized processes and robust quality controls, home care prioritizes ease of use, affordability, and remote connectivity, and hospitals and clinics require devices that integrate with point-of-care workflows and electronic medical records. Distribution channels also shape access and patient experience; hospital pharmacies manage inpatient and integrated outpatient prescriptions, online pharmacies enable direct-to-consumer convenience and subscription models, and retail pharmacies support immediate access and point-of-purchase counseling. Together, these segments form a multi-dimensional picture in which product design, technology selection, user needs, and distribution logistics intersect to determine a device or solution’s real-world suitability and adoption potential.
Regionally tailored strategic implications highlighting how differing regulatory landscapes, payer models, and care delivery realities influence adoption across the Americas, Europe Middle East and Africa, and Asia Pacific
Regional performance and strategic priorities vary considerably, driven by healthcare system structure, regulatory regimes, and demographic trends. In the Americas, a large and diverse payer landscape places a premium on real-world evidence and reimbursement clarity, with clinical integration and patient support programs driving competitive differentiation. Across Europe, the Middle East & Africa, regulatory harmonization efforts coexist with varied market maturity, necessitating tailored entry strategies that account for local approval timelines, procurement practices, and clinician education needs. Vendors operating in this region often balance centralized product strategies with decentralized commercialization tactics to accommodate heterogeneous regulatory and reimbursement environments.
Asia-Pacific presents a mosaic of opportunities characterized by rapid technology adoption in some markets and constrained access in others, where affordability and distribution reach are primary concerns. Supply chain optimization and local partnerships are frequent strategic levers in the region, enabling faster scale-up while meeting diverse regulatory expectations. Across all regions, cross-border data governance, device interoperability, and local clinical guidelines influence how devices are deployed and supported. Thus, successful regional strategies blend global product standards with locally informed commercialization, regulatory, and patient engagement plans that respond to unique healthcare delivery realities.
Key competitive dynamics and corporate strategies that reveal how product innovation, strategic partnerships, and service ecosystems are reshaping vendor differentiation
Competitive dynamics in the sector are driven by a combination of product innovation, strategic partnerships, and service-oriented differentiation. Established device manufacturers continue to invest in incremental improvements in accuracy, sensor durability, and connectivity while forging alliances with digital health vendors to extend platform value. Concurrently, emerging technology firms are pushing the envelope on non-invasive sensing and advanced signal processing, compelling incumbents to accelerate research and development cycles.
Corporate strategies vary by firm but commonly emphasize regulatory approvals, payer engagement, and channel expansion. Strategic collaborations with healthcare systems and technology partners are increasingly common as companies seek integrated value propositions that include analytics, patient engagement, and adherence support. Additionally, supply chain resilience, quality certifications, and clinical evidence portfolios are critical competitive assets that influence procurement decisions. For buyers, differentiating between vendors increasingly depends on assessing their capability to deliver not just a device but an ecosystem that supports clinical workflows, data interoperability, and measurable outcomes over time.
Actionable strategic priorities that industry leaders should implement immediately to strengthen resilience, accelerate clinical adoption, and enhance long-term competitive positioning
Industry leaders can act on several priority areas to secure competitive advantage and improve patient outcomes. First, investing in interoperable data architectures and standardized APIs will ease integration with electronic health records and third-party analytics, enabling richer clinical insights and smoother workflows. Second, diversifying manufacturing and logistics footprints reduces exposure to tariff and supplier disruptions while improving responsiveness to regional demand shifts. Third, developing comprehensive reimbursement strategies that couple clinical evidence generation with payer engagement will accelerate adoption in value-conscious settings.
In parallel, companies should enhance user-centered design to increase adherence across home and clinic settings, pairing device improvements with education and engagement programs that support behavior change. Strategic partnerships-ranging from software integrators to local distribution partners-can expand reach and reduce time-to-market. Finally, embedding post-market surveillance and real-world evidence collection into product lifecycles will support continuous improvement, regulatory compliance, and stronger payer conversations. By aligning these actions with clear metrics and cross-functional governance, leaders can translate strategic intent into measurable operational advances.
A rigorous mixed-methods research approach detailing primary interviews, device and regulatory reviews, and triangulation processes that underpin the report’s findings
The research underpinning this executive summary combines qualitative and quantitative approaches designed to ensure robustness and triangulation. Primary research included structured interviews with clinical leaders, procurement specialists, and supply chain managers to capture firsthand insights into adoption drivers and operational constraints. These perspectives were complemented by device-level technical reviews and regulatory documentation analysis to assess compliance trajectories and product differentiation. Secondary research drew on publicly available regulatory filings, clinical guidelines, and device registries to validate themes and identify longitudinal trends.
Data integrity was maintained through cross-validation across sources and transparent documentation of assumptions and inclusion criteria. Geographic and segment sampling ensured that findings reflect a diversity of care settings and distribution models. Limitations include variable public disclosure practices across jurisdictions and evolving regulatory interpretations that may affect near-term milestones; consequently, readers are encouraged to consider the findings as a structured synthesis of current evidence rather than definitive predictions. Where possible, references to primary interview insights are anonymized to preserve confidentiality while retaining practical applicability for decision-makers.
Concise synthesis of how technological convergence and reimbursement realities are driving stakeholders to prioritize interoperability, evidence, and resilient commercialization approaches
The convergence of sensing advances, digital integration, and evolving care models positions blood glucose testing at an inflection point where devices are becoming components of broader clinical ecosystems rather than standalone products. This shift has operational implications across procurement, clinical workflows, and supply chain management, particularly as stakeholders navigate tariff-related uncertainties and region-specific regulatory landscapes. The cumulative effect is a market environment that rewards adaptability: manufacturers and providers that can combine technical excellence with interoperability, resilient logistics, and evidence-based reimbursement strategies are best placed to succeed.
Looking ahead, the emphasis on longitudinal data, patient-centric design, and value-based outcomes will continue to shape both commercial strategies and clinical adoption. Organizations that prioritize cross-functional collaboration, invest in real-world evidence generation, and pursue pragmatic partnerships will be better equipped to respond to regulatory changes and payer expectations. Ultimately, effective execution will require aligning product development, commercialization, and post-market support to deliver measurable improvements in care delivery and patient experience.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of continuous glucose monitoring systems integrated with smartphone applications to enhance real-time data tracking and patient engagement
- 5.2. Emergence of non-invasive glucose sensing technologies leveraging spectroscopy and optical sensors for pain-free monitoring experiences
- 5.3. Expansion of AI-driven predictive analytics in blood glucose management to forecast hyperglycemic and hypoglycemic events
- 5.4. Growing demand for personalized diabetes management platforms offering customized insulin dosing recommendations based on user-specific glucose patterns
- 5.5. Rise of cloud-based remote monitoring solutions enabling healthcare providers to access patient glucose data for telemedicine consultations
- 5.6. Development of implantable biosensors with long-term stability for continuous subcutaneous glucose measurement in chronic diabetes care
- 5.7. Integration of wearable glucose monitoring devices with digital therapeutics to support lifestyle interventions and medication adherence
- 5.8. Increasing focus on advanced test strip chemistry to improve accuracy and reduce interference from hematocrit and medications
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Blood Glucose Testing Market, by Product Type
- 8.1. Blood Glucose Meters
- 8.2. Control Solutions
- 8.3. Lancets
- 8.4. Sensors
- 8.4.1. Continuous Glucose Monitoring Sensors
- 8.4.2. Flash Glucose Monitoring Sensors
- 8.5. Test Strips
- 9. Blood Glucose Testing Market, by Technology
- 9.1. Electrochemical Sensors
- 9.2. Optical Techniques
- 9.3. Thermal Techniques
- 10. Blood Glucose Testing Market, by End User
- 10.1. Diagnostic Laboratories
- 10.2. Home Care
- 10.3. Hospitals And Clinics
- 11. Blood Glucose Testing Market, by Distribution Channel
- 11.1. Hospital Pharmacies
- 11.2. Online Pharmacies
- 11.3. Retail Pharmacies
- 12. Blood Glucose Testing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Blood Glucose Testing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Blood Glucose Testing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. ACON Laboratories, Inc
- 15.3.3. AgaMatrix, Inc.
- 15.3.4. ARKRAY, Inc.
- 15.3.5. Ascensia Diabetes Care Holdings AG
- 15.3.6. B. Braun Medical Ltd.
- 15.3.7. Becton Dickinson and Company
- 15.3.8. Beurer Belgium
- 15.3.9. Dexcom, Inc.
- 15.3.10. Johnson & Johnson
- 15.3.11. LifeScan IP Holdings, LLC
- 15.3.12. Medtronic PLC
- 15.3.13. Neogen Corporation
- 15.3.14. Nipro Corporation
- 15.3.15. Nova Biomedical
- 15.3.16. Roche Diagnostics Nederland BV
- 15.3.17. Rossmax International Ltd.
- 15.3.18. Sanofi S.A.
- 15.3.19. Sinocare Inc.
- 15.3.20. Terumo Corporation
- 15.3.21. Trividia Health, Inc.
- 15.3.22. VivaChek Laboratories Inc.
- 15.3.23. Medisana AG
- 15.3.24. ForaCare Suisse AG
- 15.3.25. Omron Healthcare, Inc.
- 15.3.26. Microlife AG
- 15.3.27. Merck KGaA
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
